Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paricalcitol vs Maxacalcitol in Japanese Hemodialysis Patients with SHPT
NCT01341782Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2011
- Primary completion
- Apr 2012
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of paricalcitol in secondary hyperparathyroidism (SHPT) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Percentage of Participants With Target Intact Parathyroid Hormone (iPTH) and Without Hypercalcemia at 13 weeks. Started May 2011; status: completed.
02
Drugs
paricalcitol
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT01341782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01341782.